|Bid||51.30 x 800|
|Ask||51.85 x 900|
|Day's range||50.40 - 53.07|
|52-week range||28.39 - 90.20|
|Beta (5Y monthly)||0.93|
|PE ratio (TTM)||65.20|
|Earnings date||06 Dec 2021 - 10 Dec 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||41.19|
Enphase Energy's (ENPH) IQ7+ microinverters have been selected for a 1.2 MW private power grid in New South Wales. The move strengthens its position in Australia.
AUSTIN, Texas, September 28, 2021--Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company has strengthened its leadership team with the appointments of Mark S. Berger, M.D. to the newly-created position of Chief Medical Officer and Hemant Kumar, Ph.D., CPM, EMBA to the newly-created position of Chief Manufacturing and Technology Officer.
Solar stocks have emerged as some of the worst-hit among the many sectors feeling the heat from growing contagion fears as the Evergrande crisis continues to unfold